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Introduction
Pituitary surgery represents the ﬁrst-line treatment for most
patients with Cushing’s disease (CD) [1, 2].
In the case of surgery failure, additional treatment options
are required [3–6]. Pasireotide has shown favourable results
in the ﬁrst-line treatment of patients with CD, who are not
candidates for surgery or in the second-line when surgery
has failed [7–9]. The aim of the current study is to compare
the effects of surgery and pasireotide treatment in a cohort of
patients with CD, and to evaluate the differences in response
rate in terms of hormonal and clinical control, and
improvement of metabolic complications.
Materials and methods
This retrospective study analysed data of ten patients (8 F, 2
M; mean age 43.2± 11.8 years) with active CD despite a
previous surgery, who were treated with pasireotide and 20
gender and age-matched naïve CD patients treated by trans-
sphenoidal surgery.
According to the mean (m) of three urinary free cortisol
(UFC) levels, in the pasireotide group 7/10 had mild
[mUFC ≥ 1.5 and ≤2 times the upper limit of the normal
range (ULN)], 2/10 moderate (mUFC> 2 and ≤5 ULN) and
1/10 had severe (mUFC> 5 ULN) CD. In the surgery group,
10/20 had mild, 6/20 moderate and 4/20 severe CD.
Before treatment with pasireotide, 8/10 patients were
diabetic, metformin-treated, while 2/10 patients had normal
glucose tolerance. Pasireotide was administered at the dose
of 600 μg twice daily, with an increase to 900 μg twice
daily, for those patients who did not normalise mUFC levels
after 3 months.
The study protocol was approved by the local Ethics
Committee and a written informed consent was obtained
from all participants included in the study.
Body mass index (BMI) and waist circumference (WC),
lipids, HbA1c, glycaemia and insulinaemia fasting and
during oral glucose tolerance test were eveluated at baseline
and after 12 months of treatment. Insulin secretion was
evaluated by HOMA-β, the oral disposition index (DIo) and
the area under the curve of insulin (AUC2-h insulin), while
insulin sensitivity was assessed by ISI Matsuda [10–12].
To evaluate the difference between surgery and pasir-
eotide treatment in terms of efﬁcacy, the Δ value was cal-
culated as the difference between 12 months of therapy and
baseline, for those parameters, which were statistically
signiﬁcant at the t-Student.
Insulin, glycaemia and lipids were measured using
standard methods (Modular P800, Roche, Milan). HbA1c
was determined by high performance liquid chromato-
graphy with an ion-exchange resin (Bio-Rad Laboratories,
Milan, Italy). Adrenocorticotropic hormone (ACTH) and
urinary free cortisol (UFC) were detected by electro-
chemiluminescence immunoassay (Elecsys, Roche, Milan).
Statistical analysis
The Statistical Packages for Social Science SPSS version 17
(SPSS, Inc.) was used for data analysis. Data were pre-
sented as mean± SD for continuous variables, and rates and
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proportions were calculated for categorical variables. The
differences between groups were evaluated with the t-Stu-
dent for quantitative variables and χ2 for trend for catego-
rical variables. A p value <0.05 was considered statistically
signiﬁcant.
Results
Both surgery and pasireotide treatments resulted in a sig-
niﬁcant decrease of BMI (p< 0.001) and WC (p< 0.001
and p= 0.003) compared to baseline (Table 1).
A signiﬁcant decrease in ACTH and mUFC levels was
observed both after surgery (both p< 0.001) and pasireotide
(p= 0.014 and p= 0.001, respectively) (Table 1).
In the pasireotide group, 8/10 patients normalised mUFC
with the dose of 600 μg. Two patients did not normalise
mUFC, despite the increase to 900 μg. One of them, who
had moderate CD, had a decrease of approximately 60%,
while the other one, who had severe CD, had a decrease of
about 55% compared to baseline. In the surgery group, 2/20
patients, both with moderate disease, did not normalise
mUFC levels. Additionally, surgery resulted in a signiﬁcant
decrease in Δ_ACTH (p= 0.001) and Δ_mUFC (p 0.019)
compared to pasireotide.
When comparing the Δ_mUFC according to the severity
of CD, no difference in Δ_mUFC was found between
pasireotide and surgery in patients with mild and moderate
hypercortisolism. In patients with severe hypercortisolism,
surgery proved more effective in reducing mUFC levels
than pasireotide (p= 0.035), though only one patient treated
with pasireotide had severe hypercortisolism. Comparing
the Δ_ACTH according to the severity of CD, surgery
proved more effective in reducing ACTH levels in patients
with mild (p= 0.019) and moderate (p= 0.039) CD than
pasireotide, while no differences were observed in patients
with severe disease (data not shown).
A signiﬁcant reduction in total cholesterol (TC) was
observed both after surgery (p= 0.015) and pasireotide (p
= 0.012) (Table 1). Surgery resulted in a signiﬁcant
reduction in LDL-C (p= 0.045) and ﬁbrinogen (p= 0.009)
(Table 1). Conversely, pasireotide was associated with a
signiﬁcant increase in fasting glycaemia (p= 0.002),
HbA1c (p= 0.011) and AUC2h-glycaemia (p= 0.007)
concomitant to a signiﬁcant decrease in fasting insulinaemia
(p= 0.018), HOMAβ (p= 0.002) and AUC2h-insulinaemia
Table 1 Clinical, hormonal, metabolic and clotting parameters, insulin secretion and sensitivity indexes, in patients treated by surgery and with
pasireotide at baseline and after 12 months
Surgery (N= 20) Pasireotide (N= 10)
Baseline Mean± SD 12 months Mean± SD p Baseline Mean± SD 12 months Mean ± SD p
Clinical parameters
BMI (Kg/m2) 29.3± 3.9 25.4± 3.97 <0.001 38.6± 9.8 32.9± 8.1 <0.001
WC (cm) 100.5± 8.8 93.1± 9.09 <0.001 117.3± 15.7 110.1± 16.1 0.003
Hormonal parameters
ACTH (pmol/l) 15.9± 4.6 5.3± 1.7 <0.001 14.8± 4.2 11.2± 4.6 0.001
mUFC (nmol/24 h) 1049.5± 637.2 310.1± 206.8 <0.001 683.1± 522.1 337.4± 254.1 0.001
Metabolic parameters
TC (mmol/l) 5.57± 1.23 4.87± 1.24 0.015 5.41± 0.94 4.93± 0.73 0.012
HDL cholesterol (mmol/l) 1.31± 0.32 1.26± 0.36 0.699 1.56± 0.46 1.57± 0.43 0.928
Triglycerides (mmol/l) 1.83± 0.87 1.48± 0.59 0.169 1.45± 0.57 1.25± 0.55 0.194
LDL cholesterol (mmol/l) 3.3± 1.02 2.78± 1.15 0.045 3.17± 0.86 2.89± 0.74 0.214
Atherogenic index 0.11± 0.3 0.05± 0.31 0.619 −0.04± 0.3 −0.12± 0.29 0.179
Fasting glycaemia (mmol/l) 5.26± 1.99 4.79± 1.59 0.215 5.79± 1.1 7.19± 1.77 0.002
HbA1c (mmol/mol) 44.1± 11.1 44.9± 12.5 0.780 42.9± 5.8 50.2± 10.8 0.011
AUC 2h glycaemia (mmol/l 120 min) 1255.6± 389.9 901.8± 212.7 0.146 944.5± 461 802.6± 430.9 0.007
Insulin secretion indexes
Fasting insulinaemia (UI/ml) 13.3± 8.16 7.37± 3.43 0.056 18.5± 10.1 9.1± 5.34 0.018
HOMA β 153.1± 97.4 112.7± 45.1 0.233 141.18± 61.6 63.1± 36.1 0.002
DIo 1.05± 1.41 4.84± 4.88 0.358 2.29± 0.75 −0.34± 4.8 0.405
AUC 2h insulinaemia (microU/ml 120 min) 9218.1± 6342.2 8805.1± 3992.7 0.907 9059.2± 3523.8 5893± 5418.1 0.047
Insulin sensitivity indexes
ISI Matsuda 2.48± 0.54 6.71± 5.12 0.324 3.73± 1.08 8.67± 4.65 0.076
Clotting parameters
INR 0.85± 0.19 0.98± 0.05 0.103 0.91± 0.07 0.92± 0.05 0.556
aPTT (sec) 25.9± 4.73 29.1± 2.15 0.075 27.1± 5.26 25.6± 4.75 0.177
Fibrinogen (mg/dl) 356.4± 71.1 248.8± 71.5 0.009 355.4± 111.8 326.5± 42.58 0.285
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(p= 0.047), without a signiﬁcant effect on DIo and ISI-
Matsuda (Table 1).
Discussion
The current study shows that 12 months of both pasireotide
treatment and surgery result in effective control of hormonal
and clinical parameters in patients with CD. However,
pasireotide leads to an increase in glycaemic values and a
decrease in insulin secretion, without any interference on
insulin sensitivity, as already described [13]. The impair-
ment of glucose metabolism in the group of pasireotide was
more evident in patients with pre-existing diabetes mellitus,
while one patient without pre-existing glucose metabolism
defects did not experience hyperglycaemia. This may be
related to the interaction of individual factors, such as age,
genetic predisposition and lifestyle, and disease-related
factors such as duration and degree of hypercortisolism,
which may act in favouring diabetes mellitus [14, 15] and
consequently may determine more susceptibility to the
pasireotide hyperglycaemic effect.
We reported normalisation of mUFC and ACTH levels in
18/20 patients (90%) treated with surgery and in 8/10 (80%)
treated with pasireotide. The good control of disease with
pasireotide appears to be in disagreement with the results of
the phase III study, which reported a 34.2% of full and
partial control of disease [5]. However, the phase III study
included 78% of patients with moderate to severe CD, while
the current study focused especially on patients with mild
disease, who might appear as the patients with highest
beneﬁt from pasireotide, while only a small number (20%)
had moderate disease and only one patient had severe dis-
ease. Comparing surgery and pasireotide treatment, surgery
proved more effective in reducing mUFC than pasireotide in
patients with severe disease and, in reducing ACTH in
patients with moderate and severe disease, while no dif-
ferences between the two treatments, in terms of mUFC and
ACTH decrease, were observed in patients with mild CD.
Surgery resulted in a decrease in LDL-C and ﬁbrinogen,
while no effect was observed in the pasireotide group,
which maybe related to the hyperglycaemic effect [16–18].
As far as we know, this is the ﬁrst study directly com-
paring pasireotide and surgery treatments. However, some
study limitations should be considered. This study was
performed on a small cohort of patients with CD. The
period of observation was quite short and the most part of
patients treated with pasireotide had mild hypercortisolism.
In conclusion, these preliminary data suggest that pasir-
eotide and surgery are effective in CD control in terms of
decrease of visceral obesity and hormonal parameters,
which are strong cardiovascular risk factors [19]. Surgery
efﬁcacy appears to be comparable with pasireotide in
patients with mild hypercortisolism, while it appears to be
much stronger in patients with moderate and severe CD.
Therefore, further larger studies are required to evaluate the
long-term effects of both treatments on hormonal and
clinical parameters, especially in patients with severe CD.
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